Next-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection

Wang, Ting; Sung, Tzu-Cheng; Chen, Yu; Lin, Huang; Chen, Yen-Hung; Zhu, Zhe-Wei; Gong, Jian Ping; Pan, Jiandong; Higuchi, Akon

doi:10.1039/d3tb00308f

Cited by 11 publications

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address these challenges, interdisciplinary collaboration is essential [ 266 ]. Combining expertise in biomedical science, nanotechnology, materials science, and other fields strengthens research cooperation and helps to jointly overcome technical problems [ 267 ]. In addition, the guidance and norms of regulatory policies should be strengthened to ensure the safety and effectiveness of LNPs in clinical applications.…”

Section: Future Prospects and Challengesmentioning

confidence: 99%

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Wu,

Li,

Qian

et al. 2024

Vaccines

View full text Add to dashboard Cite

In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great research interest. mRNA vaccines are a potential choice for tumor immunotherapy, due to their ability to directly encode antigen proteins and stimulate a strong immune response. However, the mode of delivery and lack of stability of mRNA are key issues limiting its application. LNPs are an excellent mRNA delivery carrier, and their structural stability and biocompatibility make them an effective means for delivering mRNA to specific targets. This study summarizes the research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. The role of LNPs in improving mRNA stability, immunogenicity, and targeting is discussed. This review aims to systematically summarize the latest research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity to provide new ideas and strategies for tumor immunotherapy, as well as to provide more effective treatment plans for patients.

show abstract

Section: Future Prospects and Challengesmentioning

confidence: 99%

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Wu,

Li,

Qian

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…In addressing these challenges, interdisciplinary collaboration is essential [266] . Combining expertise in biomedical science, nanotechnology, materials science and other fields strengthens research cooperation and jointly overcomes technical problems [267] . In addition, the guidance and norms of regulatory policies should be strengthened to ensure the safety and effectiveness of LNPs in clinical applications [268] .…”

Section: Future Prospects and Challengesmentioning

confidence: 99%

Lipid Nanoparticle (LNP) Delivery Vector-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Wu,

Li,

Qian

et al. 2023

Preprint

View full text Add to dashboard Cite

Lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy in recent years. The strategy of targeting immune cells in cancer therapy has become a research area of great interest. mRNA vaccines are a potential choice for tumor immunotherapy due to their ability to directly encode antigen proteins and stimulate a strong immune response. However, the mode of delivery and lack of stability of mRNA are key issues limiting its application. LNPs are an excellent mRNA delivery vector, and their structural stability and biocompatibility make them an effective means to deliver mRNA to specific targets. This study summarizes the research progress in LNP delivery vector-assisted targeted controlled release mRNA vaccines in tumor immunity. The role of LNPs in improving mRNA stability, immunogenicity and targeting is discussed. In addition, combined with the cutting-edge research results, the potential mechanisms and application prospects of LNP-mRNA vaccines in tumor immunotherapy were further analyzed. This review aims to systematically summarize the latest research progress in LNP delivery carrier-assisted targeted controlled-release mRNA vaccines in tumor immunity to provide new ideas and strategies for tumor immunotherapy and provide more effective treatment plans for patients.

show abstract

Kinetically Controlled Polyelectrolyte Complex Assembly of microRNA‐Peptide Nanoparticles toward Treating Mesothelioma

Anderson,

Singh,

Stephens

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Broad size distributions and poor long‐term colloidal stability of microRNA‐carrying nanoparticles, especially those formed by polyelectrolyte complexation, represent major hurdles in realizing their clinical translation. Herein, peptide design is used alongside optimized flash nanocomplexation (FNC) to produce uniform peptide‐based miRNA particles of exceptional stability that display anticancer activity against mesothelioma in vitro and in vivo. Modulating the content and display of lysine‐based charge from small intrinsically disordered peptides used to complex miRNA proved essential in achieving stable colloids. FNC facilitates kinetic isolation of the mechanistic steps involved in particle formation to allow the preparation of particles of discrete size in a highly reproducible, scalable, and continuous manner, facilitating pre‐clinical studies. To our knowledge, this work represents the first example of employing FNC to prepare polyelectrolyte complexes of miRNA and peptide. Encapsulation of these particles into an injectable hydrogel matrix allows for their localized in vivo delivery by syringe. A one‐time injection of a gel containing particles composed of miRNA‐215‐5p and the peptide PKM1 limited tumor progression in a xenograft model of mesothelioma.This article is protected by copyright. All rights reserved

show abstract

Next-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection

Abstract: RNA, including mRNA, siRNA and miRNA, is part of a new class of patient treatments that prevent and treat several diseases. As an alternative to DNA therapy using plasmid DNA,...

Cited by 11 publications

References 99 publications

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Lipid Nanoparticle (LNP) Delivery Vector-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Kinetically Controlled Polyelectrolyte Complex Assembly of microRNA‐Peptide Nanoparticles toward Treating Mesothelioma

Contact Info

Product

Resources

About